Gastroenterology

Cynthia Ann Moylan, MD

Associate Professor of Medicine
Assoicate Professor in Pathology
Member of the Duke Cancer Institute
Campus mail 905 S Lasalle St, Gsrb1, DUMC 3256, Durham, NC 27710
Phone (919) 668-0401
Email address cynthia.moylan@duke.edu

My research interests focus on the study of chronic liver disease and primary liver cancer, particularly from nonalcoholic fatty liver disease (NAFLD).  As part of the NAFLD Research Team at Duke, I am investigating the role of epigenetics and genetics on the development of advanced fibrosis from NAFLD.  The long term goal of our research is to develop non-invasive biomarkers to identify those patients at increased risk for cirrhosis and end stage liver disease in order to risk stratify patients as well as to develop better preventative and therapeutic strategies.  

Education and Training

  • Fellow in Gastroenterology, Medicine, Duke University, 2005 - 2009
  • Resident, Medicine, Duke University, 2002 - 2005
  • M.D., University of Miami, 2002

Grants

Publications

Oloruntoba, OO, and Moylan, CA. ""Too Female" for Liver Transplantation." Hepatology (Baltimore, Md.) 68, no. 6 (December 2018): 2424-2425.

PMID
29679376
Full Text

Wildman-Tobriner, B, Middleton, MM, Moylan, CA, Rossi, S, Flores, O, Chang, ZA, Abdelmalek, MF, Sirlin, CB, and Bashir, MR. "Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis." Gastroenterology 155, no. 5 (November 2018): 1428-1435.e2.

PMID
30031769
Full Text

Glass, O, Henao, R, Patel, K, Guy, CD, Gruss, HJ, Syn, W-K, Moylan, CA, Streilein, R, Hall, R, Mae Diehl, A, and Abdelmalek, MF. "Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease." Hepatology Communications 2, no. 11 (November 2018): 1344-1355.

PMID
30411081
Full Text

Wilder, J, Choi, SS, and Moylan, CA. "Vibration-Controlled Transient Elastography for Diagnosing Cirrhosis and Staging Hepatic Fibrosis." Jama 320, no. 19 (November 2018): 2031-2032.

PMID
30383175
Full Text

Moylan, CA, Sorrow, PA, Mavis, A, Bashir, M, Jima, D, Maguire, R, Bozdogan, E, Buie, S, Murphy, SK, Diehl, AM, Hoyo, C, and Abdelmalek, MF. "Obesity and Nonalcoholic Fatty Liver Disease in Childhood Associate with Altered DNA Methylation in Early Life." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Moylan, CA, Sorrow, PA, Mavis, A, Bashir, M, Jima, D, Maguire, R, Bozdogan, E, Buie, S, Murphy, SK, Diehl, AM, Hoyo, C, and Abdelmalek, MF. "Obesity and Nonalcoholic Fatty Liver Disease in Childhood Associate with Altered DNA Methylation in Early Life." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chaudhry, M, Moylan, CA, Middleton, MS, Farjat, A, Chaudhury, KR, Guy, CD, Abdelmalek, MF, Loomba, R, Sirlin, CB, and Bashir, M. "Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chaudhry, M, Moylan, CA, Middleton, MS, Farjat, A, Chaudhury, KR, Guy, CD, Abdelmalek, MF, Loomba, R, Sirlin, CB, and Bashir, M. "Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Harrison, SA, Guy, CD, Bashir, M, Frias, JP, Alkhouri, N, Baum, S, Taub, RA, Moylan, CA, Bansal, MB, Neuschwander-Tetri, BA, and Moussa, S. "In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Harrison, SA, Guy, CD, Bashir, M, Frias, JP, Alkhouri, N, Baum, S, Taub, RA, Moylan, CA, Bansal, MB, Neuschwander-Tetri, BA, and Moussa, S. "In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Pages